Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer

Journal of Biological Chemistry

Volumn 290, Issue 4, 2015, Pages 2024-2033

  Shao, Chen ^a   Ahmad, Nihal ^b   Hodges, Kurt ^c   Kuang, Shihuan ^a   Ratliff, Tim ^a   Liu, Xiaoqi ^a  

^a Purdue University   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CELL DEATH; CELL PROLIFERATION; CELLS; CYTOLOGY; UROLOGY;

ANDROGEN-DEPENDENT; ANTI-DIABETIC DRUGS; ANTINEOPLASTIC; ANTINEOPLASTIC ACTIVITY; CO TREATMENTS; POLO-LIKE KINASE 1; PROSTATE CANCERS; THERAPEUTIC STRATEGY;

DISEASES;

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; ANDROGEN; GLUTAMINE; MEMBRANE PROTEIN; METFORMIN; POLO LIKE KINASE 1; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; PROTEIN REDD1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE; PTERIDINE DERIVATIVE; TP53 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TOLERABILITY; EMBRYO; ENZYME INHIBITION; GLYCOLYSIS; HORMONE DEPENDENCE; HUMAN; HUMAN CELL; IC50; MALE; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; PROSTATE CANCER; PROSTATE CANCER CELL LINE; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUMOR XENOGRAFT; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; CELL CYCLE; CELL PROLIFERATION; CELL SEPARATION; DISEASE COURSE; DRUG EFFECTS; FLOW CYTOMETRY; GENETICS; METABOLISM; MITOSIS; PROSTATE TUMOR; RNA INTERFERENCE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; CELL SURVIVAL; DISEASE PROGRESSION; FLOW CYTOMETRY; GLYCOLYSIS; HUMANS; MALE; METFORMIN; MICE; MITOSIS; NEOPLASM TRANSPLANTATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PTERIDINES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84921785817     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.596817     Document Type: Article

References (48)

1. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., and Thun, M. J. (2008) Cancer statistics, 2008. CA Cancer J. Clin. 58, 71-96
2. Goldenberg, S. L., Gleave, M. E., Taylor, D., and Bruchovsky, N. (1999) Clinical experience with intermittent androgen suppression in prostate cancer: minimum of 3 years' follow-up. Mol. Urol. 3, 287-292
3. Bruchovsky, N., Klotz, L. H., Sadar, M., Crook, J. M., Hoffart, D., Godwin, L., Warkentin, M., Gleave, M. E., and Goldenberg, S. L. (2000) Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations. Mol. Urol. 4, 191-199; discussion 201
4. Gleave, M., Goldenberg, S. L., Bruchovsky, N., and Rennie, P. (1998) Intermittent androgen suppression for prostate cancer: rationale and clinical experience. Prostate Cancer Prostatic Dis. 1, 289-296
5. Kirpichnikov, D., McFarlane, S. I., and Sowers, J. R. (2002) Metformin: an update. Ann. Int. Med. 137, 25-33
6. Ben Sahra, I., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J. F., Le Marchand-Brustel, Y., and Bost, F. (2008) The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27, 3576-3586
7. Dowling, R. J., Zakikhani, M., Fantus, I. G., Pollak, M., and Sonenberg, N. (2007) Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 67, 10804-10812
8. Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N., and Pollak, M. (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 66, 10269-10273
9. Karnevi, E., Said, K., Andersson, R., and Rosendahl, A. H. (2013) Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells. BMC Cancer 13, 235
10. Sikka, A., Kaur, M., Agarwal, C., Deep, G., and Agarwal, R. (2012) Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation. Cell Cycle 11, 1374-1382
11. Spratt, D. E., Zhang, C., Zumsteg, Z. S., Pei, X., Zhang, Z., and Zelefsky, M. J. (2013) Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur. Urol. 63, 709-716
12. Cairns, R. A., Harris, I. S., and Mak, T. W. (2011) Regulation of cancer cell metabolism. Nat. Rev. Cancer 11, 85-95
13. Vander Heiden, M. G. (2011) Targeting cancer metabolism: a therapeutic window opens. Nat. Rev. Drug Discov. 10, 671-684
14. Jones, R. G., Plas, D. R., Kubek, S., Buzzai, M., Mu, J., Xu, Y., Birnbaum, M. J., and Thompson, C. B. (2005) AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 18, 283-293
15. Bolster, D. R., Crozier, S. J., Kimball, S. R., and Jefferson, L. S. (2002) AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. J. Biol. Chem. 277, 23977-23980
16. Turner, N., Li, J. Y., Gosby, A., To, S. W., Cheng, Z., Miyoshi, H., Taketo, M. M., Cooney, G. J., Kraegen, E. W., James, D. E., Hu, L. H., Li, J., and Ye, J. M. (2008) Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes 57, 1414-1418
17. Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., Musi, N., Hirshman, M. F., Goodyear, L. J., and Moller, D. E. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167-1174
18. Ben Sahra, I., Regazzetti, C., Robert, G., Laurent, K., Le Marchand-Brustel, Y., Auberger, P., Tanti, J. F., Giorgetti-Peraldi, S., and Bost, F. (2011) Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 71, 4366-4372
19. Kalender, A., Selvaraj, A., Kim, S. Y., Gulati, P., BrÛlé, S., Viollet, B., Kemp, B. E., Bardeesy, N., Dennis, P., Schlager, J. J., Marette, A., Kozma, S. C., and Thomas, G. (2010) Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 11, 390-401
20. Liu, X., Chhipa, R. R., Pooya, S., Wortman, M., Yachyshin, S., Chow, L. M., Kumar, A., Zhou, X., Sun, Y., Quinn, B., McPherson, C., Warnick, R. E., Kendler, A., Giri, S., Poels, J., Norga, K., Viollet, B., Grabowski, G. A., and Dasgupta, B. (2014) Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK. Proc. Natl. Acad. Sci. U.S.A. 111, E435-E444
21. Sogame, Y., Kitamura, A., Yabuki, M., and Komuro, S. (2009) A comparison of uptake of metformin and phenformin mediated by hOCT1 in human hepatocytes. Biopharm. Drug Dispos. 30, 476-484
22. Segal, E. D., Yasmeen, A., Beauchamp, M. C., Rosenblatt, J., Pollak, M., and Gotlieb, W. H. (2011) Relevance of the OCT1 transporter to the antineoplastic effect of biguanides. Biochem. Biophys. Res. Commun. 414, 694-699
23. Ben Sahra, I., Le Marchand-Brustel, Y., Tanti, J. F., and Bost, F. (2010) Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol. Cancer Ther. 9, 1092-1099
24. Lapenna, S., and Giordano, A. (2009) Cell cycle kinases as therapeutic targets for cancer. Nat. Rev. Drug Discov. 8, 547-566
25. Strebhardt, K. (2010) Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat. Rev. Drug Discov. 9, 643-660
26. Hofheinz, R. D., Al-Batran, S. E., Hochhaus, A., Jäger, E., Reichardt, V. L., Fritsch, H., Trommeshauser, D., and Munzert, G. (2010) An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors. Clin. Cancer Res. 16, 4666-4674
27. McInnes, C., and Wyatt, M. D. (2011) PLK1 as an oncology target: current status and future potential. Drug Discov. Today 16, 619-625
28. Schöffski, P., Blay, J. Y., De Greve, J., Brain, E., Machiels, J. P., Soria, J. C., Sleijfer, S., Wolter, P., Ray-Coquard, I., Fontaine, C., Munzert, G., Fritsch, H., Hanft, G., Aerts, C., Rapion, J., Allgeier, A., Bogaerts, J., and Lacombe, D. (2010) Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). Eur. J. Cancer 46, 2206-2215
29. Deeraksa, A., Pan, J., Sha, Y., Liu, X. D., Eissa, N. T., Lin, S. H., and Yu-Lee, L. Y. (2013) Plk1 is upregulated in androgen-insensitive prostate cancer cells and its inhibition leads to necroptosis. Oncogene 32, 2973-2983
30. Hou, X., Li, Z., Huang, W., Li, J., Staiger, C., Kuang, S., Ratliff, T., and Liu, X. (2013) Plk1-dependent microtubule dynamics promotes androgen receptor signaling in prostate cancer. Prostate 73, 1352-1363
31. Yang, X., Li, H., Zhou, Z., Wang, W. H., Deng, A., Andrisani, O., and Liu, X. (2009) Plk1-mediated phosphorylation of Topors regulates p53 stability. J. Biol. Chem. 284, 18588-18592
32. Ando, K., Ozaki, T., Yamamoto, H., Furuya, K., Hosoda, M., Hayashi, S., Fukuzawa, M., and Nakagawara, A. (2004) Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J. Biol. Chem. 279, 25549-25561
33. Liu, X., Lei, M., and Erikson, R. L. (2006) Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol. Cell. Biol. 26, 2093-2108
34. Corey, E., Quinn, J. E., Buhler, K. R., Nelson, P. S., Macoska, J. A., True, L. D., and Vessella, R. L. (2003) LuCaP 35: a new model of prostate cancer progression to androgen independence. Prostate 55, 239-246
35. Li, Z., Li, J., Bi, P., Lu, Y., Burcham, G., Elzey, B. D., Ratliff, T., Konieczny, S. F., Ahmad, N., Kuang, S., and Liu, X. (2014) Plk1 phosphorylation of PTEN causes a tumor-promoting metabolic state. Mol. Cell. Biol. 34, 3642-3661
36. Ben Sahra, I., Laurent, K., Giuliano, S., Larbret, F., Ponzio, G., Gounon, P., Le Marchand-Brustel, Y., Giorgetti-Peraldi, S., Cormont, M., Bertolotto, C., Deckert, M., Auberger, P., Tanti, J. F., and Bost, F. (2010) Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res. 70, 2465-2475
37. Fendt, S. M., Bell, E. L., Keibler, M. A., Davidson, S. M., Wirth, G. J., Fiske, B., Mayers, J. R., Schwab, M., Bellinger, G., Csibi, A., Patnaik, A., Blouin, M. J., Cantley, L. C., Guarente, L., Blenis, J., Pollak, M. N., Olumi, A. F., Vander Heiden, M. G., and Stephanopoulos, G. (2013) Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res. 73, 4429-4438
38. Kumar, A., White, T. A., MacKenzie, A. P., Clegg, N., Lee, C., Dumpit, R. F., Coleman, I., Ng, S. B., Salipante, S. J., Rieder, M. J., Nickerson, D. A., Corey, E., Lange, P. H., Morrissey, C., Vessella, R. L., Nelson, P. S., and Shendure, J. (2011) Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc. Natl. Acad. Sci. U.S.A. 108, 17087-17092
39. Engelman, J. A. (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 9, 550-562
40. Liu, P., Cheng, H., Roberts, T. M., and Zhao, J. J. (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 8, 627-644
41. Bitting, R. L., and Armstrong, A. J. (2013) Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocr. Relat. Cancer 20, R83-R99
42. Liu, A. Y., Brubaker, K. D., Goo, Y. A., Quinn, J. E., Kral, S., Sorensen, C. M., Vessella, R. L., Belldegrun, A. S., and Hood, L. E. (2004) Lineage relationship between LNCaP and LNCaP-derived prostate cancer cell lines. Prostate 60, 98-108
43. Buzzai, M., Jones, R. G., Amaravadi, R. K., Lum, J. J., DeBerardinis, R. J., Zhao, F., Viollet, B., and Thompson, C. B. (2007) Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 67, 6745-6752
44. DeYoung, M. P., Horak, P., Sofer, A., Sgroi, D., and Ellisen, L. W. (2008) Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev. 22, 239-251
45. Ellisen, L. W., Ramsayer, K. D., Johannessen, C. M., Yang, A., Beppu, H., Minda, K., Oliner, J. D., McKeon, F., and Haber, D. A. (2002) REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol. Cell 10, 995-1005
46. Shoshani, T., Faerman, A., Mett, I., Zelin, E., Tenne, T., Gorodin, S., Moshel, Y., Elbaz, S., Budanov, A., Chajut, A., Kalinski, H., Kamer, I., Rozen, A., Mor, O., Keshet, E., Leshkowitz, D., Einat, P., Skaliter, R., and Feinstein, E. (2002) Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis. Mol. Cell. Biol. 22, 2283-2293
47. Choi, Y. W., and Lim, I. K. (2014) Sensitization of metformin-cytotoxicity by dichloroacetate via reprogramming glucose metabolism in cancer cells. Cancer Lett. 346, 300-308
48. Liu, X. S., Song, B., Elzey, B. D., Ratliff, T. L., Konieczny, S. F., Cheng, L., Ahmad, N., and Liu, X. (2011) Polo-like kinase 1 facilitates loss of Pten tumor suppressor-induced prostate cancer formation. J. Biol. Chem. 286, 35795-35800